1,3-β-D glucan measurement and its usefulness in the diagnosis of invasive fungal infections;Laboratorní stanovení 1,3-β-D-glukanu a jeho využití v diagnostice invazivních mykóz

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 14, Issue 3, 2008, Pages 88-92

  Kocmanová, Iva ^a   Racil Z ^a   Koukalova D ^b   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b Ústav Mikrobiologie LF UP ^*  (Czech Republic)

Author keywords

1,3 beta D glucan; Invasive fungal infection; Serological diagnosis

Indexed keywords

BETA 1,3 GLUCAN;

ANTIGEN DETECTION; ASPERGILLOSIS; CANDIDIASIS; CELL WALL; DIAGNOSTIC TEST; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE MYCOSIS; MYCOSIS; NONHUMAN; RELIABILITY; REVIEW; SERODIAGNOSIS;

ANTIGENS, FUNGAL; BETA-GLUCANS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 50849096123     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Zhirong Y, Wanqing L. Fungal respiratory disease. Curr Opin Pulm Med. 2006;12(3):222-227.
2. Devlin RK. Invasive fungal infections caused by Candida and Malassezia species in the neonatal intensive care unit. Adv Neonatal Care. 2006;6(2):68-77.
3. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005;366(9490):1013-1025.
4. von Eiff M, Zuhlsdorf M, Roos N, et al. Pulmonary fungal infections in patients with hematological malignancies-diagnostic approaches. Ann Hematol. 1995;70(3):135-141.
5. Ráčil Z, Kocmanová I, Wagnerová B, et al. Časná diagnostika invazivních mykotických infekcí u hematoonkologických nemocných pomocí sérologických metod. Vnitř Lék. 2007;53(9):990-999.
6. Alexander BD, Pfaller MA. Contemporary tools for diagnosis and management of invasive mycoses. Clin Infect Dis. 2006;43,Suppl 1:15-27.
7. Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses. 2007;50 Suppl 12-17.
8. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis. 2006;43(5):577-584.
9. Kedzierska A (1--> 3)-beta-D-glucan - a new marker for the early serodiagnosis of deep-seated fungal infections in humans. Pol J Microbiol. 2007;56(1):3-9.
10. Mennink-Kersten MA, Ruegebrink D, Wasei N, et al. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol. 2006;44(5):1711-1718.
11. Obayashi T, Yoshida M, Tamura H, et al. Determination of plasma (1--> 3)-beta-D-glucan: A new diagnostic aid to deep mycosis. J Med Vet Mycol. 1992;30(4):275-280.
12. Yoshida M. Usefulness of determination of beta-D-glucan in the diagnosis of deep mycosis - experience in Japan. Med Mycol. 2006;44(6),Suppl 1:185-189.
13. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39(2):199-205.
14. Wheat LJ. Galactomannan antigenemia detection for diagnosis of invasive aspergillosis. part I. Clin Microbiol Newslett. 2005;27(7):51-57.
15. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1--> 3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol. 1997;35(5):371-374.
16. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1 --> 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43(12): 5957-5962.
17. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1--> 3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42(6):2733-2741.
18. Pazos C, Ponton J, Del Palacio A. Contribution of (1--> 3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43(1):299-305.
19. Nichterlein T, Buchheidt D, Hein A, et al. Comparison of glucan detection and galactomannan enzyme immunoassay in gastrointestinal and systemic murine candidiasis. Diagn Microbiol Infect Dis. 2003;46(2):103-108.
20. Obayashi T, Yoshida M, Mori T, et al. Plasma (1--> 3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345(8941):17-20.
21. Ponton J,del Palacio A. Influence of Candida colonization on the (1--> 3) beta-D-glucan assay. Clin Infect Dis. 2006;43(2):263-264.
22. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med. 2006;354(26): 2834-2835.
23. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Reactivity of bacteria with the 1,3-beta-glucan assay (M-568). Abstract of the 47th ICAAC 2007:65.
24. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005; 41(5):654-659.
25. Upton A, Leisenring W, Marr KA. (1--> 3) beta -D-glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dig. 2006;42(7):1054-1056; author reply 1056.
26. Digby J, Kalbfleisch J, Glenn A, et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10(5):882-885.
27. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1--> 3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol. 1995;33(12):3115-3118.